NewLink Genetics Corp (NASDAQ:NLNK) Evaluates IO-Based Combination Therapies Through A New Partnership

Brendan Byrne - October 2, 2017

NewLink Genetics Corp (NASDAQ:NLNK) has today made an announcement regarding its entry into a clinical partnership agreement with AstraZeneca plc (ADR) (NYSE:AZN). The two business giants will be seeking to evaluate the combination of durvalumab with indoximod along with the standard solution of chemotherapy for persons struggling with metastatic pancreatic cancer.

The primary goal for the company’s randomized placebo-controlled, Phase 2 study will be to carry out an elaborate evaluation of the safety as well as efficacy of the immuno-oncology-based combination. These scientists will be comparing it to a combination of urvalumab with gemcitabine/ABRAXANE.

The two companies will give equal amounts towards funding the Phase 2 trial. The lead scientists have said that NewLink Genetics will be the one serving as the study sponsor. NewLink Genetics remains confident that the share of the aggregate expense on the trial won’t be having a material effect of its financial standing.

The Chief Executive Officer working with NewLink Genetics opined, “We are pleased to initiate a joint immuno-oncology clinical collaboration with AstraZeneca. As recent data have indicated, indoximod combinations with immunotherapy and chemotherapy show promise of improving outcomes for patients with multiple tumor types.”

The two hope that the US Food and Drug Administration will approve the new product. After that, the companies will right away kick-start their distribution activities. They hope to help the suffering persons from around the globe with their trusted solutions.

Asides from helping the ailing persons, the two also hope to generate high revenue streams that will help them implement major expansions. Competition in the industry has been pretty fierce compelling them to do all within their means to remain relevant as well as maintain their customers.

Cancer is a condition that has proved quite challenging to treat and has resulted in quite a large number of people losing their lives. The late-stage biopharmaceutical company, NewLink Genetics hopes that it will develop and commercialize novel immuno-oncology product candidates to help all cancer patients.

Brendan Byrne

While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email (brendanbyrne@wallstreetpr.com) or his Google+ page (https://plus.google.com/u/0/116608759701551457422).

Leave a Reply

Your email address will not be published. Required fields are marked *